{ "task": "T02 FDA CDER novel approvals Sept 2026", "expected_count": 9, "scoring": { "row_correct_if": "brand + active ingredient + date exact; indication substantively matches", "note": "The FDA page lists rows newest-first; Emcitate is row 45 and sits in a transposed block the `fda approvals` program dropped in the pilot (bugs.md #1). openFDA shows exactly 9 ORIG approvals with class 'Type 1 - New Molecular Entity' in Sept 2026, matching the page. Excluded on purpose: Type 2/5 NDAs (Lamlique, Bexlutry, Omcazio, Zueino, Degevma) and BLA Garzulys (no NME class) — not on CDER's novel list." }, "rows": [ { "brand": "Zanvastro", "active ingredient": "zilganersen", "approved on": "2026-09-03", "approved to treat": "Alexander disease in pediatric and adult patients", "application": "NDA220210", "sponsor": "Ionis", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 37: Zanvastro | zilganersen | 9/3/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ZANVASTRO%22", "quote": "NDA220210 ... submission_type ORIG, submission_status AP, submission_status_date 20260903, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Etcamah", "active ingredient": "camizestrant", "approved on": "2026-09-04", "approved to treat": "HR-positive, HER2-negative (ESR1-mutated) locally advanced or metastatic breast cancer", "application": "NDA220359", "sponsor": "AstraZeneca", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 38: Etcamah | camizestrant | 9/4/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ETCAMAH%22", "quote": "NDA220359 ... submission_type ORIG, submission_status AP, submission_status_date 20260904, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Isembyld", "active ingredient": "apitegromab-mstn", "approved on": "2026-09-11", "approved to treat": "spinal muscular atrophy in adults and pediatric patients 2 years and older", "application": "BLA761463", "sponsor": "Scholar Rock", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 39: Isembyld | apitegromab-mstn | 9/11/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ISEMBYLD%22", "quote": "BLA761463 ... submission_type ORIG, submission_status AP, submission_status_date 20260911, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Pixclara", "active ingredient": "floretyrosine F 18", "approved on": "2026-09-11", "approved to treat": "PET imaging to differentiate recurrent or progressive glioma from treatment-related change", "application": "NDA218592", "sponsor": "Telix", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 40: Pixclara | floretyrosine F 18 | 9/11/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22PIXCLARA%22", "quote": "NDA218592 ... submission_type ORIG, submission_status AP, submission_status_date 20260911, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Onswik", "active ingredient": "insulin efsitora alfa-gobe", "approved on": "2026-09-23", "approved to treat": "glycemic control in adults with type 2 diabetes mellitus", "application": "BLA761408", "sponsor": "Eli Lilly", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 41: Onswik | insulin efsitora alfa-gobe | 9/23/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ONSWIK%22", "quote": "BLA761408 ... submission_type ORIG, submission_status AP, submission_status_date 20260923, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Lyrfigtu", "active ingredient": "lirafugratinib", "approved on": "2026-09-23", "approved to treat": "previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 alteration", "application": "NDA220425", "sponsor": "Elevar", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 42: Lyrfigtu | lirafugratinib | 9/23/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22LYRFIGTU%22", "quote": "NDA220425 ... submission_type ORIG, submission_status AP, submission_status_date 20260923, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Juvmo", "active ingredient": "tavapadon", "approved on": "2026-09-25", "approved to treat": "Parkinson's disease in adults", "application": "NDA220415", "sponsor": "AbbVie", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 43: Juvmo | tavapadon | 9/25/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22JUVMO%22", "quote": "NDA220415 ... submission_type ORIG, submission_status AP, submission_status_date 20260925, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Atebrioz", "active ingredient": "zilurgisertib", "approved on": "2026-09-25", "approved to treat": "reduce new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP), adults and pediatric patients 12+", "application": "NDA221198", "sponsor": "Mirum", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 44: Atebrioz | zilurgisertib | 9/25/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ATEBRIOZ%22", "quote": "NDA221198 ... submission_type ORIG, submission_status AP, submission_status_date 20260925, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] }, { "brand": "Emcitate", "active ingredient": "tiratricol", "approved on": "2026-09-28", "approved to treat": "peripheral thyrotoxicosis in patients with MCT8 deficiency", "application": "NDA220963", "sponsor": "Rare Thyroid", "sources": [ { "kind": "primary", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", "quote": "Row 45: Emcitate | tiratricol | 9/28/2026" }, { "kind": "other", "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22EMCITATE%22", "quote": "NDA220963 ... submission_type ORIG, submission_status AP, submission_status_date 20260928, submission_class_code_description 'Type 1 - New Molecular Entity'" } ] } ], "frozen": "2026-11-12" }